Prostate Cancer and the Mevalonate Pathway.

Autor: Guerrero-Ochoa P; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain., Rodríguez-Zapater S; Minimally Invasive Research Group (GITMI), Faculty of Veterinary Medicine, University of Zaragoza, 50009 Zaragoza, Spain., Anel A; Department of Biochemistry and Molecular and Cellular Biology, Faculty of Sciences, University of Zaragoza, 50009 Zaragoza, Spain., Esteban LM; Department of Applied Mathematics, Escuela Universitaria Politécnica de La Almunia, Institute for Biocomputation and Physic of Complex Systems, Universidad de Zaragoza, 50100 La Almunia de Doña Godina, Spain., Camón-Fernández A; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain., Espilez-Ortiz R; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain.; Department of Urology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.; Area of Urology, Department of Surgery, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain., Gil-Sanz MJ; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain.; Department of Urology, Miguel Servet University Hospital, 50009 Zaragoza, Spain., Borque-Fernando Á; Health Research Institute of Aragon Foundation, 50009 Zaragoza, Spain.; Department of Applied Mathematics, Escuela Universitaria Politécnica de La Almunia, Institute for Biocomputation and Physic of Complex Systems, Universidad de Zaragoza, 50100 La Almunia de Doña Godina, Spain.; Department of Urology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.; Area of Urology, Department of Surgery, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 10; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 10.
DOI: 10.3390/ijms25042152
Abstrakt: Antineoplastic therapies for prostate cancer (PCa) have traditionally centered around the androgen receptor (AR) pathway, which has demonstrated a significant role in oncogenesis. Nevertheless, it is becoming progressively apparent that therapeutic strategies must diversify their focus due to the emergence of resistance mechanisms that the tumor employs when subjected to monomolecular treatments. This review illustrates how the dysregulation of the lipid metabolic pathway constitutes a survival strategy adopted by tumors to evade eradication efforts. Integrating this aspect into oncological management could prove valuable in combating PCa.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje